Screening, vaccination, and linkage to care will reduce the high costs associated with hepatitis B infection.
Study evaluated the optimal duration of ledipasvir/sofosbuvir for the treatment of acute hepatitis C virus (HCV) infection in HIV.
Needle/syringe programs (NSPs) have proven to be effective and moderately effective in preventing transmission of HCV infection and minimizing drug-related harms among people who inject drugs in Europe and North America, respectively.
Although it is commonly accepted that lamivudine prophylaxis should be started a few weeks before chemotherapy is administered, the best time for lamivudine discontinuation is still controversial.
Daily cannabis use remained significantly associated with lower odds of steatosis even after adjustment for BMI, which is known to be inversely correlated with cannabis use.
The FDA approves new hepatitis B virus vaccine for adults.
The rates of anti-HCV orders and tests were collected from 4 medical specialties within a 30 mile radius of University of Michigan, Ann Arbor campus.
Glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an NS5A inhibitor, exhibit potent antiviral activity across all six major HCV genotypes.
Given the ongoing shortage of liver grafts, transplantation from HCV increased-risk donors to anti-HCV-negative recipients could potentially expand the donor pool.
Patients who take aspirin may significantly reduce their risk of hepatitis B-related hepatocellular carcinoma.
The US VA has developed models of care that can be used to reduce the overall burden of HCV infection.
The high cost of DAA-based regimens remains an ethical issue and an obstacle to treatment accessibility. Shorter treatment regimens may offer substantial cost savings, improved treatment adherence, and a reduced rate of side effects.
Data have shown patients with genotype 3 HCV have faster progression of fibrosis and higher rates of cirrhosis, severe steatosis, and hepatocellular carcinoma.
Researchers from the United States and Italy examined 3 cohorts of women to study rates of miscarriage and infertility in HCV, and how early antiviral treatment can affect them.
The recommendations will be published in the November issue of the American Journal of Obstetrics and Gynecology.
Treatment of hepatitis C virus with direct-acting antivirals was tied to a 71% reduction in the risk of liver cancer.
For hepatitis B virus (HBV) carriers, hepatitis B virus core-related antigen (HBcrAg) levels are associated with progression to cirrhosis.
Only a small percentage of people with HIV/HCV co-infection receive treatment for hepatitis C.
Researchers believe new once-daily dose of ravidasvir plus sofosbuvir is effective in treatment HCV genotype-4 and may be cost effective.
The majority of patients treated with second-generation direct-acting antiviral agents achieved sustained virologic response in 12 weeks.
Primary endpoints are to achieve sustained virologic response, improve survival rates, and lower complications of HCV.
Merck announced that the development programs for two hepatitis C virus infection treatments have been discontinued.
The American Association of the Study for Liver Diseases and the Infectious Diseases Society of America have added additional guidelines for the treatment of hepatitis C virus.
Mandating health care providers to offer hepatitis C virus screening can increase screening rates and linkage to care.
Despite continual efforts aimed at finding new treatment options, HCC still has a very low 5-year survival rate, less than 20%, as many patients are diagnosed at an advanced stage of the disease.
Researchers assessed safety and tolerability throughout the 12 week study period and 24 weeks after completion of last dose of glecaprevir coformulated with pibrentasvir.
The effects of a statewide immunization effort on the transmission of hepatitis A was examined.
Minimally effective treatment of hepatitis C virus can prevent th edevelopment of chronic kidney disease.
Hepatitis B virus reactivation rates differ in patients with inflammatory arthritis.
Researchers compared HbA1c changes and use of antidiabetic medication in HCV with diabetes.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Are Antibiotic Stewardship Programs the Antidote to Antibiotic Overuse?
- Better Detection and Treatment Needed for H pylori Infections in Children
- FDA Approves New Hepatitis B Vaccine for Adults
- Strategies for Preventing Antibiotic Resistance in Acne
- Oral HPV Prevalence Higher in Men With Concurrent Genital HPV
- Study Finds Burnout Occurs in Over Half of US Surgeons
- HPV Vaccine Linked to Lower Respiratory Papillomatosis Rates
- Novel Antifungal Agent for Treatment of Aspergillus flavus Infections
- Inappropriate Antibiotic Use for Acute Bronchitis Highest in Younger Adults
- ACP, CDC Provides Best Practice Advice on Hepatitis B Management